VERVE THERAPEUTICS
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.
VERVE THERAPEUTICS
Industry:
Biotechnology Genetics Life Science
Founded:
2018-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.vervetx.com
Total Employee:
101+
Status:
Active
Contact:
+1 617 603 0070
Total Funding:
419.3 M USD
Technology used in webpage:
Amazon CrUX Top 50m AWS Global Accelerator Greenhouse
Similar Organizations
Myeloid Therapeutics
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
SmartLabs
SmartLabs builds and operates enterprise-grade labs, including multi-use R&D labs, vivariums, process development, and manufacturing suites.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Eli Lilly
Eli Lilly investment in Post-IPO Equity - Verve Therapeutics
Wellington Management
Wellington Management investment in Series B - Verve Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Verve Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Verve Therapeutics
Redmile Group
Redmile Group investment in Series B - Verve Therapeutics
Logos Capital
Logos Capital investment in Series B - Verve Therapeutics
Casdin Capital
Casdin Capital investment in Series B - Verve Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Verve Therapeutics
Novo Holdings
Novo Holdings investment in Series B - Verve Therapeutics
Biomatics Capital Partners
Biomatics Capital Partners investment in Series B - Verve Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-05-31 | Verve Therapeutics names Lister as chief scientific officer |
Official Site Inspections
http://www.vervetx.com Semrush global rank: 1.41 M Semrush visits lastest month: 18.07 K
- Host name: 23.185.0.3
- IP address: 23.185.0.3
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Verve Therapeutics"
Verve Therapeutics
Verve is advancing a pipeline of single-course in vivo gene editing programs intended to safely inactivate genes in the liver that contribute to CVD risk. Verve was purpose-built to disrupt …See details»
Our Story | Verve Therapeutics
Verve was established with a mission to solve the global health epidemic of cardiovascular disease. In 2018, Verve was founded by cardiology, gene editing and drug development pioneers seeking to find a solution for the global …See details»
Verve Therapeutics Provides Corporate Updates and Reports …
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular …See details»
Culture & Careers | Verve Therapeutics
At Verve, we are striving to build the preeminent company developing gene editing medicines to treat patients with cardiovascular disease (CVD), the leading cause of death globally and one …See details»
News Releases - Verve Therapeutics
May 31, 2024 · The Investor Relations website contains information about Verve Therapeutics's business for stockholders, potential investors, and financial analysts.See details»
Verve Therapeutics - Crunchbase Company Profile & Funding
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course …See details»
Verve Therapeutics Announces Leadership Update
BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with …See details»
Vertex and Verve Therapeutics Establish Collaboration to Discover …
Jul 20, 2022 · Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming …See details»
Sekar (Sek) Kathiresan - Chief Executive Officer, Founder - Verve ...
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to treat coronary artery disease, the most common type of heart disease and the leading …See details»
Investors | Verve Therapeutics
Verve Therapeutics, Inc. ©2024 All Rights ReservedSee details»
Release Details - Verve Therapeutics
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with …See details»
Verve Therapeutics, Inc. (VERV) - Stock Analysis
6 days ago · Get a real-time Verve Therapeutics, Inc. (VERV) stock price quote with breaking news, financials, statistics, charts and more.See details»
Verve Therapeutics - Overview, News & Similar companies
Verve Therapeutics contact info: Phone number: (617) 603-0070 Website: www.vervetx.com What does Verve Therapeutics do? Verve Therapeutics is a biotechnology company that …See details»
Verve Therapeutics Highlights Recent Company Progress and …
Nov 7, 2023 · VERVE-101, an in vivo base editing medicine delivered as a one-time intravenous infusion, is designed to inactivate the PCSK9 gene in liver cells, turning off liver production of …See details»
Verve Therapeutics Announces 2022 Anticipated Milestones and ...
Jan 10, 2022 · Verve will webcast its corporate presentation from the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 PM ET. A live webcast of the …See details»
Verve Therapeutics Announces 2022 Anticipated Milestones and ...
Jan 10, 2022 · Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from …See details»
Patients & Caregivers | Verve Therapeutics
At Verve, we are committed to putting people first and developing medicines for cardiovascular disease. Our Commitment to Patients and Caregivers. Verve is progressing single-course …See details»
Vertex and Verve Therapeutics Establish Collaboration to Discover …
BOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Verve Therapeutics, Inc. (Nasdaq: VERV) …See details»
VERV Stock Price Quote | Morningstar
Nov 15, 2024 · See the latest Verve Therapeutics Inc stock price (VERV:XNAS), related news, valuation, dividends and more to help you make your investing decisions.See details»
Verve Therapeutics Appoints Allison Dorval, Experienced Financial ...
Nov 29, 2021 · Verve’s lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby …See details»